Competitiveness in follow-on drug R&amp;D: a race or imitation?

DiMasi, Joseph A.; Faden, Laura

doi:10.1038/nrd3296

Cited by 93 publications

(53 citation statements)

References 10 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…However, the maps were less successful at showing the differences in focus between larger firms such as Pfizer, Novartis or Merck. This may suggest isomorphic pressures in the industry as leading firms are joined by fast followers into new therapeutic areas [50], which is quite likely given the industry's reputation for producing 'me-too' drugs [15]. However, we believe that this might also signal the need for new analyses requiring more sophisticated approaches, for example using keywords such as the Medical Subject Heading (MeSH) provided by PubMed [51].…”

Section: Cognitive Shifts: Diversification Of the Knowledge Basementioning

confidence: 99%

Big Pharma, Little Science? A Bibliometric Perspective on Big Pharma’s R&D Decline

Ràfols

Hoekman²,

Siepel

et al. 2012

SSRN Journal

View full text Add to dashboard Cite

There is a widespread perception that pharmaceutical R&D is facing a productivity crisis characterised by stagnation in the numbers of new drug approvals in the face of increasing R&D costs. This study explores pharmaceutical R&D dynamics by examining the publication activities of all R&D laboratories of the major European and US pharmaceutical firms during the period 1995-2009. The empirical findings present an industry in transformation. In the first place, we observe a decline of the total number of publications by large firms. Second, we show a relative increase of their external collaborations suggesting a tendency to outsource, and a diversification of the disciplinary base, in particular towards computation, health services and more clinical approaches. Also evident is a more pronounced decline in publications by both R&D laboratories located in Europe and by firms with European headquarters. Finally, while publications by Big Pharma in emerging economies sharply increase, they remain extremely low compared with those in developed countries. In summary, the trend in this transformation is one of a gradual decrease in internal research efforts and increasing reliance on external research. These empirical insights support the view that large pharmaceutical firms are increasingly becoming 'network integrators' rather than the prime locus of drug discovery.

show abstract

Section: Cognitive Shifts: Diversification Of the Knowledge Basementioning

confidence: 99%

Big Pharma, Little Science? A Bibliometric Perspective on Big Pharma’s R&D Decline

Ràfols

Hoekman²,

Siepel

et al. 2012

SSRN Journal

View full text Add to dashboard Cite

show abstract

“…However, the maps were less successful at showing the differences in focus between larger firms such as Pfizer, Novartis or Merck. This may suggest isomorphic pressures in the industry as leading firms are joined by fast followers into new therapeutic areas (DiMasi and Faden, 2011), which is quite likely given the industry's reputation for producing 'me-too' drugs (Angell, 2004, pp. 74-93)).…”

Section: Cognitive Shifts: Diversification Of the Knowledge Basementioning

confidence: 99%

Big Pharma, little science?

Ràfols

Hopkins

Hoekman

et al. 2014

Technological Forecasting and Social Change

109

View full text Add to dashboard Cite

There is a widespread perception that pharmaceutical R&D is facing a productivity crisis characterised by stagnation in the numbers of new drug approvals in the face of increasing R&D costs. This study explores pharmaceutical R&D dynamics by examining the publication activities of all R&D laboratories of the major European and US pharmaceutical firms during the period 1995-2009. The empirical findings present an industry in transformation. In the first place, we observe a decline of the total number of publications by large firms. Second, we show a relative increase of their external collaborations suggesting a tendency to outsource, and a diversification of the disciplinary base, in particular towards computation, health services and more clinical approaches. Also evident is a more pronounced decline in publications by both R&D laboratories located in Europe and by firms with European headquarters. Finally, while publications by Big Pharma in emerging economies sharply increase, they remain extremely low compared with those in developed countries. In summary, the trend in this transformation is one of a gradual decrease in internal research efforts and increasing reliance on external research. These empirical insights support the view that large pharmaceutical firms are increasingly becoming 'networks integrators' rather than the prime locus of drug discovery.Keywords: Pharmaceuticals, bibliometrics, outsourcing, Europe, globalisation, research network, innovation, collaboration Highlights  We analyse the publications by R&D laboratories of the top 15 pharmaceutical firms.  We observe a slow decline in their total number of publications and field share.  A more pronounced decline in publications by R&D laboratories located in Europe.  There is more external collaboration and research in non-traditional disciplines.  The results suggest that Big Pharma firms are increasingly network integrators.

show abstract

“…9 Joseph DiMasi and Laura Faden have found that the time between a first-in-class new drug and subsequent new drugs in the same therapeutic class has been dramatically reduced, from a median of 10.2 years in the 1970s to 2.5 years in the early 2000s. 10 Drugs in the same class compete through quality and price for preferred placement on drug formularies and physicians' choices for patient treatment.…”

Section: The Role Of Patents In Biopharmaceutical Innovationmentioning

confidence: 99%